Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03972202 · ClinicalTrials.gov registry record · NA

The Role of Cerebellum in Speech

A NA study of Healthy and Dysarthria, sponsored by University of California, San Francisco.

Active
Registry status
NA
Development phase
660
Enrollment target
3
Study locations

NCT03972202: Active NA study of Healthy and Dysarthria, sponsored by University of California, San Francisco.

NCT03972202 is a NA study of Healthy and Dysarthria that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 660 participants, roughly in line with the 647-participant average among 1,090 other Healthy trials with a reported enrollment target. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03972202, a NA study of Healthy and Dysarthria, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
660 participants
Enrollment target
3
Study locations

Study Summary

This study will investigate the how the cerebellum is involved in speech motor learning over time and short-term corrections in patients with cerebellar ataxia and healthy controls. This will be accomplished through three approaches: behavioral studies, magnetic resonance imaging (MRI), and transcranial magnetic stimulation (TMS). During behavioral studies, participants will be asked to speak into a microphone while their voice is played back over earphones, and to do other speaking tasks. MRI will be acquired to perform a detailed analysis on brain function and anatomy related to speech and the cerebellum. In healthy controls, TMS will also be performed to temporarily disrupt the cerebellum before, during, or after the participant performs speaking tasks. Patients with cerebellar ataxia and healthy volunteers will be asked to complete behavioral studies and/or MRI; healthy volunteers may be asked to additionally participate in TMS.

Primary Outcome

Percent compensation is calculated as the following ratio: -100\*(change in acoustic feature produced by the subject)/(change in acoustic feature caused by auditory feedback alteration). The negative sign ensures that changes produced by the subject that oppose the auditory feedback alteration changes are counted as positive compensation. Acoustic features used to compute percent compensation depend on the experiment performed and will include pitch or formant frequencies of subjects' output spe

Interventions

  • DEVICE TMS
  • DIAGNOSTIC_TEST MRI
  • BEHAVIORAL Speech-motor behavioral testing

Study Locations (3)

California

  • University of California, Berkeley - Berkeley
  • University of California, San Francisco - San Francisco

Wisconsin

  • University of Wisconsin--Madison - Madison

Trial Details

FieldValue
Enrollment Target 660 participants
Start Date 2019-09-15
Est. Completion 2030-05-31
Phase NA

What the registry record for NCT03972202 still lists

NCT03972202 is an interventional study that assigns participants to a tested intervention. The registered 660 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 647-participant average among 1,090 other Healthy trials with a reported enrollment target.

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which TMS is the first listed.

NCT03972202 reports a single indexed study location in California, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03972202 about?

NCT03972202 is a clinical study titled "The Role of Cerebellum in Speech". This study will investigate the how the cerebellum is involved in speech motor learning over time and short-term corrections in patients with cerebellar ataxia and healthy controls. This will be accomplished through three approaches: behavioral studies, magnetic resonance imaging (MRI), and transcra...

What is the current status of trial NCT03972202?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 660 participants. The study started on 2019-09-15. Estimated completion is 2030-05-31.

What conditions does trial NCT03972202 study?

This clinical trial studies the following conditions: Healthy, Dysarthria, Cerebellar Ataxia.

What interventions are being tested in trial NCT03972202?

The interventions under investigation include: TMS (DEVICE), MRI (DIAGNOSTIC_TEST), Speech-motor behavioral testing (BEHAVIORAL).

Who is sponsoring clinical trial NCT03972202?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03972202 being conducted?

This trial has 3 study locations across California, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03972202's enrollment target sits among peer trials

660 39th of 1090 higher than 1,052 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01185132 · 660 participants · Phase 3

    Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

  • NCT03346694 · 660 participants · NA

    Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing

  • NCT05407636 · 660 participants · Phase 3

    Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

  • NCT05470205 · 660 participants · Phase 3

    Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03972202, the US trial registry maintained by the National Library of Medicine. NCT03972202 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.